Xenetic Biosciences, Inc. (XBIO)

Xenetic Biosciences Statistics

Total Valuation

XBIO has a market cap or net worth of $6.90 million. The enterprise value is -$519,908.

Market Cap	6.90M
Enterprise Value	-519,908

Important Dates

The last earnings date was Tuesday, May 12, 2026, after market close.

Earnings Date	May 12, 2026
Ex-Dividend Date	n/a

Share Statistics

XBIO has 2.29 million shares outstanding. The number of shares has increased by 22.51% in one year.

Current Share Class	2.29M
Shares Outstanding	2.29M
Shares Change (YoY)	+22.51%
Shares Change (QoQ)	+5.10%
Owned by Insiders (%)	8.17%
Owned by Institutions (%)	1.47%
Float	1.82M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.14
Forward PS	n/a
PB Ratio	1.00
P/TBV Ratio	0.98
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.93

Current Ratio	7.93
Quick Ratio	7.67
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -37.01% and return on invested capital (ROIC) is -24.79%.

Return on Equity (ROE)	-37.01%
Return on Assets (ROA)	-21.85%
Return on Invested Capital (ROIC)	-24.79%
Return on Capital Employed (ROCE)	-34.45%
Weighted Average Cost of Capital (WACC)	16.44%
Revenue Per Employee	$1.60M
Profits Per Employee	-$1.12M
Employee Count	2
Asset Turnover	0.47
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +0.13% in the last 52 weeks. The beta is 2.22, so XBIO's price volatility has been higher than the market average.

Beta (5Y)	2.22
52-Week Price Change	+0.13%
50-Day Moving Average	3.08
200-Day Moving Average	2.92
Relative Strength Index (RSI)	50.87
Average Volume (20 Days)	11,191

Short Selling Information

The latest short interest is 7,266, so 0.32% of the outstanding shares have been sold short.

Short Interest	7,266
Short Previous Month	14,880
Short % of Shares Out	0.32%
Short % of Float	0.40%
Short Ratio (days to cover)	0.47

Income Statement

In the last 12 months, XBIO had revenue of $3.19 million and -$2.23 million in losses. Loss per share was -$1.18.

Revenue	3.19M
Gross Profit	3.19M
Operating Income	-2.39M
Pretax Income	-2.23M
Net Income	-2.23M
EBITDA	n/a
EBIT	-2.39M
Loss Per Share	-$1.18

Balance Sheet

The company has $7.35 million in cash and n/a in debt, with a net cash position of $7.35 million or $3.21 per share.

Cash & Cash Equivalents	7.35M
Total Debt	n/a
Net Cash	7.35M
Net Cash Per Share	$3.21
Equity (Book Value)	6.95M
Book Value Per Share	3.03
Working Capital	6.64M

Cash Flow

Operating Cash Flow	-1.82M
Capital Expenditures	n/a
Depreciation & Amortization	n/a
Net Borrowing	n/a
Free Cash Flow	-1.82M
FCF Per Share	-$0.79

Margins

Gross margin is 100.00%, with operating and profit margins of -75.05% and -70.03%.

Gross Margin	100.00%
Operating Margin	-75.05%
Pretax Margin	-70.03%
Profit Margin	-70.03%
EBITDA Margin	n/a
EBIT Margin	-75.05%
FCF Margin	n/a

Dividends & Yields

XBIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.51%
Shareholder Yield	-22.51%
Earnings Yield	-32.72%
FCF Yield	-26.67%

Analyst Forecast

The average price target for XBIO is $40.00, which is 1,228.90% higher than the current price. The consensus rating is "Hold".

Price Target	$40.00
Price Target Difference	1,228.90%
Analyst Consensus	Hold
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 15, 2023. It was a reverse split with a ratio of 1:10.

Last Split Date	May 15, 2023
Split Type	Reverse
Split Ratio	1:10

Scores

Altman Z-Score	n/a
Piotroski F-Score	2